Can magnetic resonance spectroscopy differentiate malignant and benign causes of lymphadenopathy? An in-vitro approach
Fig 2
Score plot of training set differentiating benign and malignant causes of lymphadenopathy with cross-validation plot.
A. t1 is the predictive component, it is used to achieve discrimination in between both groups. t1o is the orthogonal component, It is useful for understanding class variability. B. Cross-validation plot showing Tcv1 vs Tcv2 for the OPLS-DA model with three orthogonal components showing good separation of the benign and malignant groups (R2 = 0.96, Q2Y = 0.63, n = 45).